Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial

John W. Eikelboom, Lars Wallentin, Stuart J. Connolly, Mike Ezekowitz, Jeff S. Healey, Jonas Oldgren, Sean Yang, Marco Alings, Scott Kaatz, Stefan H. Hohnloser, Hans Christoph Diener, Maria Grazia Franzosi, Kurt Huber, Paul Reilly, Jeanne Varrone, Salim Yusuf

Research output: Contribution to journalArticle

Abstract

Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged

Original languageEnglish
Pages (from-to)2363-2372
Number of pages10
JournalCirculation
Volume123
Issue number21
DOIs
Publication statusPublished - May 31 2011

Fingerprint

Warfarin
Anticoagulants
Atrial Fibrillation
Hemorrhage
Therapeutics
International Normalized Ratio
Stroke
Dabigatran

Keywords

  • anticoagulants
  • atrial fibrillation

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. / Eikelboom, John W.; Wallentin, Lars; Connolly, Stuart J.; Ezekowitz, Mike; Healey, Jeff S.; Oldgren, Jonas; Yang, Sean; Alings, Marco; Kaatz, Scott; Hohnloser, Stefan H.; Diener, Hans Christoph; Franzosi, Maria Grazia; Huber, Kurt; Reilly, Paul; Varrone, Jeanne; Yusuf, Salim.

In: Circulation, Vol. 123, No. 21, 31.05.2011, p. 2363-2372.

Research output: Contribution to journalArticle

Eikelboom, JW, Wallentin, L, Connolly, SJ, Ezekowitz, M, Healey, JS, Oldgren, J, Yang, S, Alings, M, Kaatz, S, Hohnloser, SH, Diener, HC, Franzosi, MG, Huber, K, Reilly, P, Varrone, J & Yusuf, S 2011, 'Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial', Circulation, vol. 123, no. 21, pp. 2363-2372. https://doi.org/10.1161/CIRCULATIONAHA.110.004747
Eikelboom, John W. ; Wallentin, Lars ; Connolly, Stuart J. ; Ezekowitz, Mike ; Healey, Jeff S. ; Oldgren, Jonas ; Yang, Sean ; Alings, Marco ; Kaatz, Scott ; Hohnloser, Stefan H. ; Diener, Hans Christoph ; Franzosi, Maria Grazia ; Huber, Kurt ; Reilly, Paul ; Varrone, Jeanne ; Yusuf, Salim. / Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. In: Circulation. 2011 ; Vol. 123, No. 21. pp. 2363-2372.
@article{d5ea2aa12fff4188b4ad2d467dc0147f,
title = "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial",
abstract = "Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87{\%} versus 3.57{\%}; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31{\%} versus 3.57{\%}; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged",
keywords = "anticoagulants, atrial fibrillation",
author = "Eikelboom, {John W.} and Lars Wallentin and Connolly, {Stuart J.} and Mike Ezekowitz and Healey, {Jeff S.} and Jonas Oldgren and Sean Yang and Marco Alings and Scott Kaatz and Hohnloser, {Stefan H.} and Diener, {Hans Christoph} and Franzosi, {Maria Grazia} and Kurt Huber and Paul Reilly and Jeanne Varrone and Salim Yusuf",
year = "2011",
month = "5",
day = "31",
doi = "10.1161/CIRCULATIONAHA.110.004747",
language = "English",
volume = "123",
pages = "2363--2372",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation

T2 - An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial

AU - Eikelboom, John W.

AU - Wallentin, Lars

AU - Connolly, Stuart J.

AU - Ezekowitz, Mike

AU - Healey, Jeff S.

AU - Oldgren, Jonas

AU - Yang, Sean

AU - Alings, Marco

AU - Kaatz, Scott

AU - Hohnloser, Stefan H.

AU - Diener, Hans Christoph

AU - Franzosi, Maria Grazia

AU - Huber, Kurt

AU - Reilly, Paul

AU - Varrone, Jeanne

AU - Yusuf, Salim

PY - 2011/5/31

Y1 - 2011/5/31

N2 - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged

AB - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged

KW - anticoagulants

KW - atrial fibrillation

UR - http://www.scopus.com/inward/record.url?scp=79958126202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958126202&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.110.004747

DO - 10.1161/CIRCULATIONAHA.110.004747

M3 - Article

C2 - 21576658

AN - SCOPUS:79958126202

VL - 123

SP - 2363

EP - 2372

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 21

ER -